THE ROLE OF BIOPRINTING IN PERSONALIZED MEDICINE: ENGINEERING 3D PRINTED DRUG DELIVERY SYSTEMS FOR CUSTOMIZED THERAPEUTICS

Abstract

This study explores the potential of 3D printed drug delivery systems (DDS) in personalized medicine, focusing on the development and evaluation of customized therapeutics. The primary aim was to engineer bioprinted DDS capable of sustained drug release, improved bioactivity, and enhanced mechanical stability. The results demonstrated a controlled drug release over 72 hours, significantly improving therapeutic effectiveness compared to traditional drug delivery methods, which typically show rapid drug release followed by suboptimal effects. Bioactivity assays revealed a notable increase in cell viability, with the 3D printed DDS exhibiting a 95.6% cell viability rate, compared to 75.3% for traditional systems. Mechanical integrity testing confirmed that the 3D printed DDS maintained structural stability under compression, with a maximum stress at deformation of 3.5 MPa, outperforming traditional DDS. Tests on the synthesized drug delivery system indicated its high biocompatible nature by demonstrating low levels of toxicity in cytotoxicity measurements. The technical evaluations confirmed that 3D-printed DDS released medication at higher levels compared to standard versions and maintained excellent compatibility with biological networks alongside strong material strength thus establishing itself as a promising medicine customization platform. Studies indicate how 3D printed DDS system enables patient-customer tailored release methods resulting in enhanced drug control programs. This technology requires additional technical developments in suitable biomaterials along with improved clinical application scale to effectively use. The main research priority in future 3D bioprinting studies must include improvements to technology along with its clinical practicality.